Y-90, capecitabine and atezolizumab study opens in oligometastatic CRC
ClinicalTrials.gov lists a PHASE2 recruiting study of yttrium-90 radioembolization with capecitabine and atezolizumab for oligometastatic CRC, with preliminary liver disease control as the key early outcome.
ClinicalTrials.gov now lists Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC as a PHASE2 study with overall_status RECRUITING. The latest registry observation was published 2026-11-20T00:00:00+00:00, and has_results is false, so the study is still in the testing stage rather than the results stage.
For a general reader, the practical takeaway is simple: this study is looking at whether yttrium-90 radioembolization, capecitabine, and atezolizumab can work together for people with oligometastatic CRC. The primary outcome is framed around preliminary efficacy and the intrahepatic disease control rate (iDCR) at 12 weeks, which means researchers want to see how often disease in the liver is held in check after treatment.
"This record describes a study and its registry status; study outcomes require posted results." — source: ctgov_v2
What the study is measuring
The study title and arm structure show a single experimental approach: yttriuM-90 in combination with capEcitabine and aTezolizumab. The intervention listed is yttrium-90 radioembolization, grouped under that experimental arm.
Its primary outcome uses RECIST 1.1, a standard method for measuring whether tumors shrink, stay stable, or grow. Here, the definition is limited to liver findings at first post-Y-90 follow-up imaging, and the record says disease control includes complete response, partial response, or stable disease within the liver at 12 weeks.
"Disease control rate is defined as the proportion of patients with complete response (CR), partial response (PR), or stable disease (SD) within the liver at first post-Y-90 follow-up imaging by NCI's response evaluation criteria in solid tumors (RECIST 1.1), which is a standard way to measure if th
Timeline and status
Brown University is listed as sponsor, and the primary_completion_date is 2027-04-01 with primary_completion_type ESTIMATED. That means the timeline is still a forecast, not a finished readout.
Because no results are posted yet, the most useful public signal is the registry status itself: the study is recruiting now, the main efficacy check is set at 12 weeks, and the record does not provide an outcome. Readers following Cancer Breakthroughs can watch this study as part of a wider stream of cancer research updates rather than as a completed advance.
"Study outcomes require posted results." — source: ctgov_v2